Description: ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Home Page: www.anipharmaceuticals.com
210 Main Street West
Baudette,
MN
56623
United States
Phone:
218 634 3500
Officers
| Name | Title |
|---|---|
| Mr. Nikhil Lalwani | President, CEO & Director |
| Mr. Stephen P. Carey | Senior VP of Finance & CFO |
| Mr. Chad Gassert | Senior Vice President of Corporate Development & Strategy |
| Mr. Christopher K. Mutz | Senior VP & Head of Rare Disease |
| Mr. Ori Gutwerg | Senior Vice President of Generics |
| Mr. Muthusamy Shanmugam MS R.Ph. | Head of R&D, COO of Novitium Operations & Director |
| Mr. James G. Marken | Senior Vice President of Operations |
| Ms. Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease |
| Ms. Meredith W. Cook J.D. | Senior VP, General Counsel & Corporate Secretary |
| Ms. Krista L. Davis | Senior VP & Chief Human Resources Officer |
Exchange: STU
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.0662 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9047 |
| Price-to-Sales TTM: | 2.0154 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 642 |